Schizoaffective Disorder clinical trials
80 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Synbiotic Compound to Reduce Symptoms of Schizophrenia
- Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
- Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- Acetazolamide for Treatment Resistant Schizophrenia
- Cognitive Training for Emotion Regulation in Psychotic Disorders
- Effectiveness of Motivation Skills Training (MST)
- Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
- Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
- Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder
- A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
- Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
- Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
- Ocrelizumab for Psychosis by Autoimmunity
- Anticholinergic Deprescription in Schizophrenia
- Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy
- Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
- Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
- Exercise and Olanzapine-samidorphan
- MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
- Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
- Biomarkers to Enhance Early Schizophrenia Treatment
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
- CLOZAPINE Response in Biotype-1
- Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
- iTBS to Enhance Social Cognition in People With Psychosis
- Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
- REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
- Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
- Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)
- Neural Biomarkers of Electroconvulsive Therapy Response
- Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
- Enhanced Coordinated Specialty Care for Early Psychosis
- Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
- CBT-CP for Veterans With SMI
- Enhancing Rehabilitation for Veterans With Serious Mental Illness
- Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Enhancing Veteran-Clinical Collaboration in VA PRRCs
- Database Registry for Neural Network Biomarkers in Psychosis
- MicroRNAs as Biomarkers in First Episode Schizophrenia
- Social Isolation and Aging in Schizophrenia
- Neurophysiologic Biomarkers for Cognitive Rehabilitation
- Transition Care for FEP
- Cognitive Strategies in Early Psychosis 2
- Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Anti-Inflammatory Challenge in Schizophrenia
- Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
- Neuronal Effects of Exercise in Schizophrenia
- Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
- Visual Perception in Schizophrenia
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Schizoaffective Disorder” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.